513001
PD 98059
≥98% (HPLC), MAPK pathway inhibitor and AMPK activator, liquid
别名:
InSolution PD 98059, MEK Inhibitor V
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H13NO3
化学文摘社编号:
分子量:
267.28
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
PD 98059, InSolution, ≥98%, 5 mg/ml, reversible inhibitor of MAP Kinase Kinase (MEK)
SMILES string
Nc1c(cccc1c2[o]c3c([c](c2)=O)cccc3)OC
InChI
1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3
InChI key
QFWCYNPOPKQOKV-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
liquid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
shipped in
wet ice
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
MAP kinase kinase (MEK)
MAP kinase kinase (MEK)
Product does not compete with ATP.
Reversible: yes
Target IC50: 2 µM in completely blocking the 4-fold increase in MAP kinase activity produced by nerve growth factor in PC12 cells
Disclaimer
Toxicity: Irritant (B)
General description
Selective and cell-permeable inhibitor of MAP kinase kinase (MEK) that acts by inhibiting the activation of MAP kinase and subsequent phosphorylation of MAP kinase substrates. Pretreatment of PC-12 cells with PD 98059 completely blocks the 4-fold increase of MAP kinase activity produced by nerve growth factor (NGF; IC50 = 2 µM); however, it has no effect on NGF-dependent tyrosine phosphorylation of the pp140trk receptor or its substrate Shc and does not block NGF-dependent activation of PI 3-kinase. Inhibits cell growth and reverses the phenotype of ras-transformed BALB 3T3 mouse fibroblasts and rat kidney cells.
Other Notes
Kültz, D., et al. 1998. J. Biol. Chem.273, 13645.
Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA92, 7686.
Langlois, W.J., et al. 1995. J. Biol. Chem.270, 25320.
Pang, L., et al. 1995. J. Biol. Chem.270, 13585.
Waters, S.B., et al. 1995. J. Biol. Chem.270, 20883.
Selected Citations
Lee, J., et al. 2009. Cell Stem Cell5, 76.
Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA92, 7686.
Langlois, W.J., et al. 1995. J. Biol. Chem.270, 25320.
Pang, L., et al. 1995. J. Biol. Chem.270, 13585.
Waters, S.B., et al. 1995. J. Biol. Chem.270, 20883.
Selected Citations
Lee, J., et al. 2009. Cell Stem Cell5, 76.
Packaging
Packaged under inert gas
Physical form
A 5 mg/ml solution of PD 98059 (Cat. No. 513000) in anhydrous DMSO.
Preparation Note
Following initial thaw, aliquot and freeze.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
188.6 °F - closed cup - (Dimethylsulfoxide)
flash_point_c
87 °C - closed cup - (Dimethylsulfoxide)
Rita Pepponi et al.
International journal of molecular sciences, 23(7) (2022-04-13)
Niemann Pick type C disease (NPC) is a rare disorder characterized by lysosomal lipid accumulation that damages peripheral organs and the central nervous system. Currently, only miglustat is authorized for NPC treatment in Europe, and thus the identification of new
Jue Wang et al.
Journal of cellular physiology, 235(3), 2557-2568 (2019-09-10)
Glycochenodeoxycholate (GCDA) is closely associated with carcinogenesis and chemoresistance of hepatocellular carcinoma (HCC). Signal transducer and activator of transcription 3 (STAT3), a transcription factor, is involved in various human tumors. Whether GCDA induces chemoresistance through STAT3 and the mechanism of
Chia-Ching Lin et al.
Nature communications, 12(1), 3878-3878 (2021-07-01)
Different levels of regulatory mechanisms, including posttranscriptional regulation, are needed to elaborately regulate inflammatory responses to prevent harmful effects. Terminal uridyltransferase 7 (TUT7) controls RNA stability by adding uridines to its 3' ends, but its function in innate immune response
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持